GOLDSPIRE
Live / Registered — Registered (as of 22 Oct 2024)
What this means for you
Registered since 22 Oct 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97597040
- Registration number
- 7545537
- Mark type
- Stylized text
- Filed
- 19 Sept 2022
- Published for opposition
- 13 Feb 2024
- Registered
- 22 Oct 2024
- Attorney of record
- Zachary J. Holdsman
Goods and services
- Class 042 — Scientific and technological services: Scientific research, design and development of personalized whole tumor-derived cell-based autologous immunotherapies for the treatment of cancers; providing a proprietary technology platform for the development of pharmaceutical products and devices featuring technology capable of eliciting anti-tumor responses via the release of tumor antigenic signatures and immunostimulatory factors that activate the adaptive immune system against tumor cells
Owner
- Imvax, Inc., Philadelphia, PA, US
- Imvax, Inc., Philadelphia, PA, US
- Imvax, Inc., Philadelphia, PA, US
Prosecution history
- 22 Oct 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 22 Oct 2024 — REGISTERED-PRINCIPAL REGISTER
- 19 Sept 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 19 Sept 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 29 Aug 2024 — ASSIGNED TO EXAMINER
- 30 Apr 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 09 Apr 2024 — USE AMENDMENT FILED
- 30 Apr 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 09 Apr 2024 — TEAS STATEMENT OF USE RECEIVED
- 09 Apr 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 Feb 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 Feb 2024 — PUBLISHED FOR OPPOSITION
- 24 Jan 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 06 Jan 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 04 Jan 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED